Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results

Table 1 Patient characteristics

Characteristic	3DCRT (n=47)	IMRT (n=47)	P value
	No. of patients (%)	No. of patients (%)
Sex			0.37
Male	35(74.5)	31(66.0)
Female	12(25.5)	16(34.0)
Age, years			0.37
Median range	44(20–70)	43(14–73)
≤60	42(89.4)	39(83.0)
>60	5(10.6)	8(17.0)
ECOG score			0.24
0	22(46.8)	27(57.4)
1	20(42.6)	19(40.4)
2	5(10.6)	1(2.1)
Stage			0.60
IE	39(83.0)	37(78.7)
IIE	8(17.0)	10(21.3)
B symptoms			0.10
Absent	29(61.7)	21(44.7)
Present	18(38.3)	26(55.3)
LDH level			0.63
Normal	35(74.5)	37(78.7)
Elevated	12(25.5)	10(21.3)
Primary site			0.24
Unilatera nasal cavity limited	16(34.0)	11(23.4)
Bilateral nasal cavity limited	5(10.6)	1(2.1)
nasal cavity lesions with limited invasion ^a	9(19.1)	15(31.9)
nasal cavity lesions with extensive invasion^b	10(21.3)	13(27.6)
Non-nasal cavity originated^c	7(14.9)	7(14.9)
mIPI			0.30
0	23(48.9)	28(59.6)
1	20(42.6)	13(27.6)
2-3	4(8.5)	6(12.8)
Induction chemotherapy			<0.01
None	10(21.3)	1(2.1)
CEOP	27(57.4)	2(4.2)
DICE	10(21.3)	44(93.6)

^anasal cavity lesions with limited invasion: the tumor invaded nasal cavity and one neighboring anatomic structure (pnasal sinus or nasopharynx).
^bnasal cavity lesions with extensive invasion: the tumor invaded nasal cavity and two or more neighboring anatomic structures(pnasal sinuses, nasopharynx, oropharynx or laryngopharynx).
^cNon-nasal cavity originated: the tumor originated from nasopharynx, oropharynx, laryngopharynx or tonsil.
Abbreviations: LDH lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, mIPI Stage-modified International Prognostic Index, CEOP cyclophosphamide, epirubicin, vincristine prednisone, DICE etoposide. cyclophosphamide cisplatin, dexamethasone.

ISSN: 1748-717X